Browsing Tag
BioMarin Pharmaceutical Inc.
3 posts
BioMarin Pharmaceutical (Nasdaq: BMRN) secures FDA approval to expand PALYNZIQ use in adolescents with phenylketonuria
Find out how BioMarin Pharmaceutical Inc.’s FDA approval for adolescent PALYNZIQ use could reshape PKU treatment and long-term disease control.
FDA grants priority review for BioMarin’s PALYNZIQ to treat adolescents with phenylketonuria (PKU)
Find out how BioMarin’s PALYNZIQ priority review could transform PKU treatment for adolescents and reshape the company’s rare-disease strategy.
BioMarin shares rise as new VOXZOGO and PALYNZIQ data reinforce market potential
Discover how BioMarin’s latest clinical data on VOXZOGO and PALYNZIQ at ACMG 2025 offers promising insights into rare disease treatments and what it means for the market.